Skip to main content
SpringerLink
Log in

Microtubule Stabilizing Agents in Clinical Oncology

The Taxanes

  • Chapter
The Role of Microtubules in Cell Biology, Neurobiology, and Oncology

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

The taxanes are a versatile and important class of drugs that target microtubules. Paclitaxel and docetaxel are some of the most widely used cancer chemofherapeutic agents in clinical oncology. In this chapter, we discuss the most common dose and treatment schedules, clinical efficacy, and the toxicity profiles of these agents in detail.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247–1259.

    Article  PubMed  CAS  Google Scholar 

  2. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004–1014.

    Article  PubMed  CAS  Google Scholar 

  3. Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic — thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995;55:753–760.

    PubMed  CAS  Google Scholar 

  4. Manfredi JJ, Fant J, Horwitz SB. Taxol induces the formation of unusual arrays of cellular microtubules in colchicine-pretreated J774.2 cells. Eur J Cell Biol 1986;42:126–134.

    PubMed  CAS  Google Scholar 

  5. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665–667.

    Article  PubMed  CAS  Google Scholar 

  6. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643–2655.

    PubMed  CAS  Google Scholar 

  7. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;55–61.

    Google Scholar 

  8. Lamendola DE, Duan Z, Penson RT, Oliva E, Seiden MV. β tubulin mutations are rare in human ovarian carcinoma. Anticancer Res 2003;23:681–686.

    PubMed  CAS  Google Scholar 

  9. Urano N, Fujiwara Y, Hasegawa S, et al. Absence of β-tubulin gene mutation in gastric carcinoma. Gastric Cancer 2003;6:108–112.

    PubMed  CAS  Google Scholar 

  10. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11:2127–2135.

    PubMed  CAS  Google Scholar 

  11. Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 1995;6:699–704.

    PubMed  CAS  Google Scholar 

  12. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454–1457.

    PubMed  CAS  Google Scholar 

  13. Akerley W. Recent developments in weekly paclitaxel therapy in lung cancer. Curr Oncol Rep 2001;3:165–169.

    Article  PubMed  CAS  Google Scholar 

  14. Marchetti P, Urien S, Cappellini GA, Ronzino G, Ficorella C. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 2002;44(suppl):S3–S13.

    Article  PubMed  Google Scholar 

  15. Markman M. Weekly paclitaxel in the management of ovarian cancer. Semin Oncol 2000;27:37–40.

    PubMed  CAS  Google Scholar 

  16. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353–3361.

    PubMed  CAS  Google Scholar 

  17. Alberola V, Cortesi E, Juan O. Weekly paclitaxel in the treatment of metastatic and/or recurrent nonsmall cell lung cancer. Crit Rev Oncol Hematol 2002;44(suppl):S31–S41.

    Article  PubMed  Google Scholar 

  18. Takimoto CH, Rowinsky EK. Dose-intense paclitaxel: deja vu all over again? J Clin Oncol 2003;21: 2810–2814.

    Article  PubMed  CAS  Google Scholar 

  19. Citron ML. Dose density in adjuvant chemotherapy for breast cancer. Cancer Invest 2004;22: 555–568.

    Article  PubMed  CAS  Google Scholar 

  20. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439.

    Article  PubMed  CAS  Google Scholar 

  21. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180–190.

    PubMed  CAS  Google Scholar 

  22. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995;1:599–606.

    PubMed  CAS  Google Scholar 

  23. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994;35:304–311.

    Article  PubMed  CAS  Google Scholar 

  24. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993;15:107–115.

    PubMed  Google Scholar 

  25. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263–1268.

    PubMed  CAS  Google Scholar 

  26. Grem JL, Tutsch KD, Simon KJ, et al. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 1987;71:1179–1184.

    PubMed  CAS  Google Scholar 

  27. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654–2666.

    PubMed  CAS  Google Scholar 

  28. Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. Support Care Cancer 2003; 11:270–277.

    PubMed  Google Scholar 

  29. Raghavan VT, Bloomer WD, Merkel DE. Taxol and radiation recall dermatitis. Lancet 1993; 341:1354.

    Article  PubMed  CAS  Google Scholar 

  30. Shenkier T, Gelmon K. Paclitaxel and radiation-recall dermatitis. J Clin Oncol 1994; 12:439.

    PubMed  CAS  Google Scholar 

  31. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1–6.

    Article  PubMed  CAS  Google Scholar 

  32. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699–708.

    Article  PubMed  CAS  Google Scholar 

  33. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320–1329.

    PubMed  Google Scholar 

  34. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–3200.

    Article  PubMed  CAS  Google Scholar 

  35. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96: 1682–1691.

    Article  PubMed  CAS  Google Scholar 

  36. Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 2003;89(suppl 3): S9–S15.

    Article  PubMed  CAS  Google Scholar 

  37. McGuire WP 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003;89(suppl 3):S3–S8.

    Article  PubMed  CAS  Google Scholar 

  38. Thigpen T. First-line therapy for ovarian carcinoma: what’s next? Cancer Invest 2004;22(suppl 2): 21–28.

    Article  PubMed  CAS  Google Scholar 

  39. Omura GA, Brady MF, Look KY, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol 2003;21:2843–2848.

    Article  PubMed  CAS  Google Scholar 

  40. Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 2000; 1:32–40; discussion 41–32.

    Article  PubMed  CAS  Google Scholar 

  41. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983.

    Article  PubMed  CAS  Google Scholar 

  42. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999;17:2355–2364.

    PubMed  CAS  Google Scholar 

  43. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000;18:724–733.

    PubMed  CAS  Google Scholar 

  44. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588–592.

    Article  PubMed  Google Scholar 

  45. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707–1715.

    PubMed  CAS  Google Scholar 

  46. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002;20: 3114–3121.

    Article  PubMed  CAS  Google Scholar 

  47. Bernard-Marty C, Cardoso F, Piccart MJ. Use and abuse of taxanes in the management of metastatic breast cancer. Eur J Cancer 2003;39:1978–1989.

    Article  PubMed  CAS  Google Scholar 

  48. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.

    Article  PubMed  CAS  Google Scholar 

  49. Crown J, O’Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004;9(suppl 2):24–32.

    Article  PubMed  CAS  Google Scholar 

  50. Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997;15:1906–1915.

    PubMed  CAS  Google Scholar 

  51. Ishitobi M, Shin E, Kikkawa N. Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel. Int J Clin Oncol 2001;6:55–58.

    Article  PubMed  CAS  Google Scholar 

  52. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxelresistant metastatic breast cancer. J Clin Oncol 1998; 16:3362–3368.

    PubMed  CAS  Google Scholar 

  53. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001;6(suppl 3):30–35.

    Article  PubMed  CAS  Google Scholar 

  54. Miles D, von Minckwitz G, Seidman AD. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002;7(suppl 6): 13–19.

    PubMed  CAS  Google Scholar 

  55. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412–3417.

    PubMed  CAS  Google Scholar 

  56. Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004;10:3249–3261.

    Article  PubMed  CAS  Google Scholar 

  57. Simon GR, Bunn PA Jr. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest 2003;21:87–104.

    Article  PubMed  CAS  Google Scholar 

  58. Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 2004;9(suppl 2):16–23.

    Article  PubMed  CAS  Google Scholar 

  59. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074–1080.

    Article  PubMed  CAS  Google Scholar 

  60. Socinski MA, Rosenman JG, Schell MJ, et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformai thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. Cancer 2000;89:534–542.

    Article  PubMed  CAS  Google Scholar 

  61. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210–3218.

    PubMed  CAS  Google Scholar 

  62. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98.

    Article  PubMed  CAS  Google Scholar 

  63. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinumbased doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285–4291.

    Article  PubMed  CAS  Google Scholar 

  64. Kosmidis P, Mylonakis N, Skarlos D, et al. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000;11:799–805.

    Article  PubMed  CAS  Google Scholar 

  65. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 1998;16:1112–1121.

    PubMed  CAS  Google Scholar 

  66. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol 1999;17:1876–1883.

    PubMed  CAS  Google Scholar 

  67. Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. Oncologist 2000;5:199–208.

    Article  PubMed  CAS  Google Scholar 

  68. Hainsworth JD, Burris HA 3rd, Greco FA. Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. Semin Oncol 2001;28:43–47.

    Article  PubMed  CAS  Google Scholar 

  69. Van Cutsem E. The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 2004;9(suppl 2):9–15.

    Article  PubMed  Google Scholar 

  70. Olson KB, Pienta KJ. Recent advances in chemotherapy for advanced prostate cancer. Curr Urol Rep 2000; 1:48–56.

    Article  PubMed  CAS  Google Scholar 

  71. Greco FA, Gray J, Burris HA 3rd, Erland JB, Morrissey LH, Hainsworth JD. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 2001;7:203–212.

    PubMed  CAS  Google Scholar 

  72. Markman M, Fowler J. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol Oncol 2004;92:180–182.

    Article  PubMed  CAS  Google Scholar 

  73. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003;4:489–497.

    Article  PubMed  Google Scholar 

  74. Younes A. Paclitaxel-based treatment of lymphoma. Semin Oncol 1999;26:123–128.

    PubMed  CAS  Google Scholar 

  75. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophorfree, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038–1044.

    PubMed  CAS  Google Scholar 

  76. Langer CJ. CT-2103: emerging utility and therapy for solid tumours. Expert Opin Invest Drugs 2004;13:1501–1508.

    Article  CAS  Google Scholar 

  77. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747–2755.

    Article  PubMed  CAS  Google Scholar 

  78. Rowinsky EK, Tolcher AW. Antimicrotuble agents. In: De Vita VT, Hellman S, Rosenberg SA. eds. Cancer: Principles & Practice of Oncology. 7th edition. Philadelphia, Lippincott, Williams & Wilkins, 2005:390–416.

    Google Scholar 

  79. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99–114.

    Article  PubMed  CAS  Google Scholar 

  80. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5–30.

    Article  PubMed  CAS  Google Scholar 

  81. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998;16:3426–3432.

    PubMed  CAS  Google Scholar 

  82. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341–2354.

    PubMed  CAS  Google Scholar 

  83. Nabholtz J, Falkson G, Campos D, et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC. Proc Am Soc Clin Oncol 1999;18:127A.

    Google Scholar 

  84. Mackey JR, Paterson A, Dirix LY, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002;21:35A.

    Google Scholar 

  85. Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87:1210–1215.

    Article  PubMed  CAS  Google Scholar 

  86. Bontenbal M, Braun JJ, Creemers GJ, et al. Phase III study comarpring AT (adriamycin, docetaxel) to FAC (fluorouracil, adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). Eur J Cancer 2003;1:5201–5202.

    Google Scholar 

  87. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35: 1194–1201.

    Article  PubMed  CAS  Google Scholar 

  88. Jones SE, Erban J, Overmoyer B, et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542–5551.

    Article  PubMed  CAS  Google Scholar 

  89. Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004;30: 333–342.

    Article  PubMed  CAS  Google Scholar 

  90. O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812–2823.

    Article  PubMed  CAS  Google Scholar 

  91. Seidman AD. Gemcitabine and docetaxel in metastatic breast cancer. Oncology (Huntingt) 2004;18:13–16.

    Google Scholar 

  92. Mavroudis D, Malamos N, Polyzos A, et al. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. Oncology 2004;67:250–256.

    Article  PubMed  CAS  Google Scholar 

  93. Nabholtz J-M, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002;21:36A.

    Google Scholar 

  94. Smith IE, Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2001;2:561–570.

    Article  PubMed  CAS  Google Scholar 

  95. Heys SD, Eremin JM, Sarkar TK, Hutcheon AW, Ah-See A, Eremin O. Role of multimodality therapy in the management of locally advanced carcinoma of the breast. J Am Coll Surg 1994;179:493–504.

    PubMed  CAS  Google Scholar 

  96. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96–102.

    PubMed  Google Scholar 

  97. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645–652.

    Article  PubMed  CAS  Google Scholar 

  98. NSABP. The effect of primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27. Breast Cancer Res Treat 2001;69:210.

    Google Scholar 

  99. von Minckwitz G, Raab G, Schuette M, et al. Dose-dense versus sequential adriamcycin / docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2,M0) primary endpoint analysis of the GEPARDUO-Study. Proc Am Soc Clin Oncol 2002;21:43A.

    Google Scholar 

  100. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456–1466.

    Article  PubMed  CAS  Google Scholar 

  101. Evans TRJ, Gould A, Foster E, Crown JP, Leonard RCF, Mansi JL. Phase III randomised trial of adriamycin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer: an ACCOG study. Proc Am Soc Clin Oncol 2002;21:35A.

    Google Scholar 

  102. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241–2251.

    Article  PubMed  CAS  Google Scholar 

  103. Robert N, Leyland-Jones B, Asmar L, et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S37.

    Google Scholar 

  104. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095–2103.

    PubMed  CAS  Google Scholar 

  105. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinumcontaining chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354–2362.

    PubMed  CAS  Google Scholar 

  106. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145–157.

    Article  PubMed  CAS  Google Scholar 

  107. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016–3024.

    Article  PubMed  CAS  Google Scholar 

  108. Gulley J, Dahut WL. Chemotherapy for prostate cancer: finally an advance Am J Ther 2004;11:288–294.

    Article  PubMed  Google Scholar 

  109. Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003;170:1709–1716.

    Article  PubMed  CAS  Google Scholar 

  110. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–1520.

    Article  PubMed  CAS  Google Scholar 

  111. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512.

    Article  PubMed  CAS  Google Scholar 

  112. Posner MR, Lefebvre JL. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2003;88:11–17.

    Article  PubMed  CAS  Google Scholar 

  113. Haller DG, Misset JL. Docetaxel in advanced gastric cancer. Anticancer Drugs 2002; 13:451–460.

    Article  PubMed  CAS  Google Scholar 

  114. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Huntingt) 2002;16:89–96.

    Google Scholar 

  115. Budman DR, Petroni GR, Johnson JL, et al. Phase II trial of docetaxel in non-Hodgkin’s lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol 1997;15:3275–3279.

    PubMed  CAS  Google Scholar 

  116. Hong WK. The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review. Oncology (Huntingt) 2002;6:9–15.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. South Texas Accelerated Research Therapeutics (START), San Antonio, TX

    Chris H. Takimoto MD, PhD, FACP

  2. Division of Hematology Medical Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, TX

    Muralidhar Beeram MD

Authors
  1. Chris H. Takimoto MD, PhD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muralidhar Beeram MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

    Tito Fojo MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Takimoto, C.H., Beeram, M. (2008). Microtubule Stabilizing Agents in Clinical Oncology. In: Fojo, T. (eds) The Role of Microtubules in Cell Biology, Neurobiology, and Oncology. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-336-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-336-3_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-294-0

  • Online ISBN: 978-1-59745-336-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation